ReviewClinical and experimental gastroenterology2018
Proton pump inhibitor-refractory gastroesophageal reflux disease: challenges and solutions.
Review in Clinical and experimental gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- A systematic review and meta-analysis of randomized controlled trials: the effect of potassium-competitive acid blockers on nighttime symptoms of gastroesophageal reflux disease.Esophagus : official journal of the Japan Esophageal Society · 2026Pooled it
- Treatment Response With Potassium-competitive Acid Blockers Based on Clinical Phenotypes of Gastroesophageal Reflux Disease: A Systematic Literature Review and Meta-analysis.Journal of neurogastroenterology and motility · 2024Pooled it
- The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis.Esophagus : official journal of the Japan Esophageal Society · 2021Pooled it
- A preliminary report on the use of Midodrine in treating refractory gastroesophageal disease: Randomized Double-Blind Controlled Trial.Acta bio-medica : Atenei Parmensis · 2020Trial
- Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.Alimentary pharmacology & therapeutics · 2019Trial
- Yeokwisan Attenuates Reflux-Induced Esophageal Injury and Suppresses Macrophage Inflammatory Responses Associated with MAPK/PI3K-Akt and NF-κB/COX-2 Signaling.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Safety and Efficacy of Fixed-Dose Pantoprazole and Sustained Release Levosulpiride for Short-Term Management of Gastroesophageal Reflux Disease.Gastroenterology research · 2026Article
- Serum microRNAs for the assessment of symptomatically refractory gastroesophageal reflux disease despite acid suppression.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Laryngopharyngeal reflux current developments and therapeutic strategies.BMC gastroenterology · 2026Review
- A Historical and Scientific Review of Anti-Reflux Surgery: Evolution, Evidence, and Future Directions.Current gastroenterology reports · 2026Review
- Awareness, attitudes, and clinical utilization of vonoprazan for Helicobacter pylori infection and gastroesophageal reflux disease among Chinese physicians: a nationwide cross-sectional study.BMC gastroenterology · 2025Article
- Associations between excessive supragastric belching and esophageal reflux factors in patients with PPI-refractory GERD in Japan.Journal of gastroenterology · 2025Article
- The Cost Effectiveness of Adjunctive Treatments for Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease.Clinical drug investigation · 2024Article
- Pilot study evaluating salivary bile acids as a diagnostic biomarker of laryngopharyngeal reflux.Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus · 2024Article
- Review article: Diagnosis and management of laryngopharyngeal reflux.Alimentary pharmacology & therapeutics · 2024Review
- Narrative review of relationship between chronic cough and laryngopharyngeal reflux.Frontiers in medicine · 2024Review
- Article
- Review
- Gastro-esophageal reflux disease (GERD) after peroral endoscopic myotomy (POEM).Surgical endoscopy · 2022Article
- Nutritional Management of Children With Neurological Impairment in China: Current Status and Future Directions.JPGN reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
A significant percentage of patients with gastroesophageal reflux disease (GERD) will not respond to proton pump inhibitor (PPI) therapy. The causes of PPI-refractory GERD are numerous and diverse, and include adherence, persistent acid, functional disorders, nonacid reflux, and PPI bioavailability. The evaluation should start with a symptom assessment and may progress to imaging, endoscopy, and monitoring of esophageal pH, impedance, and bilirubin. There are a variety of pharmacologic and procedural interventions that should be selected based on the underlying mechanism of PPI failure. Pharmacologic treatments can include antacids, prokinetics, alginates, bile acid binders, reflux inhibitors, and antidepressants. Procedural options include laparoscopic fundoplication and LINX as well as endoscopic procedures, such as transoral incisionless fundoplication and Stretta. Several alternative and complementary treatments of possible benefit also exist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.